Antihistamines to Avoid in Arrhythmia
Avoid terfenadine, astemizole, diphenhydramine, orphenadrine, and hydroxyzine in patients with arrhythmias or prolonged QT interval, as these agents can cause fatal ventricular arrhythmias including torsades de pointes. 1, 2
High-Risk Antihistamines (Contraindicated)
The following antihistamines are specifically contraindicated due to documented QT prolongation and arrhythmogenic potential:
Withdrawn from Market
- Terfenadine - Blocks cardiac K+ channels (hERG/IKr), causes QT prolongation and torsades de pointes 2, 3
- Astemizole - Similar mechanism to terfenadine, associated with fatal arrhythmias 2, 4
Still Available (Avoid in Arrhythmia)
- Diphenhydramine - Contraindicated in long QT syndrome 1
- Orphenadrine - Contraindicated in long QT syndrome 1
- Hydroxyzine - Contraindicated in long QT syndrome 1
Safe Alternatives
The following second-generation antihistamines have NOT been associated with QT prolongation or torsades de pointes and can be used with caution:
- Fexofenadine - No electrocardiographic effects even at supratherapeutic doses 1, 2
- Loratadine/Desloratadine - Does not inhibit cardiac K+ channels at therapeutic levels 1, 2
- Cetirizine/Levocetirizine - No QT effects documented 1, 2
- Ebastine - No published QT effects 1
- Azelastine - No electrocardiographic effects 2
Critical Risk Factors to Assess
When prescribing any antihistamine to patients with arrhythmia concerns, evaluate these specific factors per the 2023 Canadian Cardiovascular Society guidelines 5:
Patient-Specific Risks
- QTc ≥500 ms - Highest risk threshold for torsades de pointes 5
- Female sex - Higher risk for acquired long QT syndrome 5
- Elderly patients - Increased susceptibility 5
- Structural heart disease - Elevates risk 5
Medication Interactions
Critical drug combinations that dramatically increase risk:
- Macrolide antibiotics (erythromycin > azithromycin) with antihistamines 5, 4
- Imidazole antifungals (ketoconazole, itraconazole) - inhibit hepatic metabolism 4
- Concurrent use of other QT-prolonging drugs 5
Metabolic Factors
- Hypokalemia - Especially with concurrent diuretic use 5
- Hypomagnesemia - Monitor closely 5
- Hepatic insufficiency - Prevents metabolism of terfenadine/astemizole 2
- Renal impairment - May require dose adjustments 5
Practical Management Algorithm
Check baseline QTc if patient has known arrhythmia, congenital long QT, or is on other QT-prolonging drugs 5
Verify drug interactions using www.crediblemeds.org before prescribing 5
Select from safe alternatives (fexofenadine, loratadine, cetirizine, levocetirizine) 1, 2
Avoid combining antihistamines with macrolides or azole antifungals - choose alternative antibiotics (penicillins, cephalosporins) instead 5
Monitor electrolytes if patient is on diuretics or has renal dysfunction 5
Do NOT use if QTc >500 ms or if QTc increases by >60-70 ms from baseline 5
Key Mechanistic Understanding
The dangerous antihistamines block the hERG potassium channel (IKr current), which delays ventricular repolarization and prolongs the QT interval 3. This creates the substrate for early afterdepolarizations and dispersion of repolarization, triggering torsades de pointes through a re-entry mechanism 3, 6. The safer second-generation agents do not significantly inhibit these cardiac channels at clinically achievable blood levels 2.
Common Pitfall
The most dangerous scenario is combining an antihistamine with drugs that inhibit hepatic metabolism (macrolides, azole antifungals), which causes accumulation to toxic levels even at normal doses 4. This is how most fatalities occurred with terfenadine and astemizole. Always check for these interactions before prescribing, even with "safer" antihistamines.